Journal of Addictive Diseases最新文献_第4页

Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases. 辅助口服纳曲酮治疗酒精使用障碍接受可注射纳曲酮缓释治疗的患者的突破渴望：3例

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-08-13 DOI: 10.1080/10550887.2026.2692669

Gabriel Felipe Tosta, Ruan Pablo Duarte Freitas, Maria Alamir, Ajitpaul Basra, Brandon Salzman, Jared Harp, Brian S Barnett, Akhil Anand

{"title":"Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases.","authors":"Gabriel Felipe Tosta, Ruan Pablo Duarte Freitas, Maria Alamir, Ajitpaul Basra, Brandon Salzman, Jared Harp, Brian S Barnett, Akhil Anand","doi":"10.1080/10550887.2026.2692669","DOIUrl":"10.1080/10550887.2026.2692669","url":null,"abstract":"Craving is a subjective, poorly characterized phenomenon strongly associated with return to use in alcohol use disorder and remains difficult to manage. Extended-release naltrexone is a U.S. Food and Drug Administration-approved, evidence-based treatment, yet some patients experience brief, intense \"breakthrough\" craving despite adherence. Although expert guidance references oral naltrexone supplementation as an option during extended-release naltrexone maintenance, published peer-reviewed case descriptions documenting this clinical scenario are lacking. We describe three adults with severe alcohol use disorder receiving monthly extended-release naltrexone who reported late-cycle breakthrough craving and were offered adjunct, as-needed oral naltrexone. All patients reported subjective improvement in craving control and continued engagement in treatment. These cases highlight a clinically observed pattern of late-cycle breakthrough craving that warrants prospective evaluation.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148723126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A whole-person framework for clinical coherence in residential substance use treatment: the Four Dimensions of Resilience. 住宅物质使用治疗临床一致性的全人框架：弹性的四个维度。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-14 DOI: 10.1080/10550887.2026.2692688

Jerome Lerner

{"title":"A whole-person framework for clinical coherence in residential substance use treatment: the Four Dimensions of Resilience.","authors":"Jerome Lerner","doi":"10.1080/10550887.2026.2692688","DOIUrl":"https://doi.org/10.1080/10550887.2026.2692688","url":null,"abstract":"Residential substance use treatment programs deliver a wide range of evidence-based interventions addressing biological, psychological, and social dimensions of recovery. Despite this comprehensive approach, care across phases of treatment often becomes fragmented, limiting clinical coherence and obscuring residual risk of return to use at key transition points. This article introduces the Four Dimensions of Resilience, a whole-person organizing structure designed to integrate multidisciplinary care across intake, treatment planning, and discharge in residential substance use treatment. The model conceptualizes recovery capacity across four interacting domains: resilient biology, emotional tone, cognitive orientation, and interpersonal connection. Rather than proposing new interventions, the model functions as an organizing structure that integrates existing evidence-based practices into a unified clinical map, supporting interdisciplinary communication and continuity of care. Practical applications across the residential continuum-including assessment, treatment planning, and discharge evaluation-are described. By providing a shared language for whole-person recovery, this approach may help treatment programs enhance clinical coherence and improve identification of residual vulnerability to return to use.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using the Reina trust and betrayal model as a framework for substance use disorder-supportive workplaces. 使用雷纳信任和背叛模型作为物质使用障碍支持工作场所的框架。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-11 DOI: 10.1080/10550887.2026.2697961

Aysha Jawed

{"title":"Using the Reina trust and betrayal model as a framework for substance use disorder-supportive workplaces.","authors":"Aysha Jawed","doi":"10.1080/10550887.2026.2697961","DOIUrl":"https://doi.org/10.1080/10550887.2026.2697961","url":null,"abstract":"Background: Substance use disorders are prevalent among employees, making workplaces important settings for prevention, treatment engagement, and long-term recovery. However, many organizations continue to rely on punitive responses that discourage disclosure, increase stigma, and contribute to costly employee turnover.Objective(s): Apply the Reina Trust and Betrayal Model as a practical framework for addressing substance use disorders in the workplace through supportive accountability, trust preservation, and recovery-oriented organizational practices.Methods: This commentary integrates the Reina Trust and Betrayal Model with federal recovery-ready workplace guidance and literature on workplace-supported recovery. The model's three domains (contractual, communication and competence trust) are examined pertaining to substance use-related workplace events, including disclosure, treatment leave, return-to-work transitions, and return to use. The framework is used to identify managerial behaviors that balance employee support with workplace safety and performance expectations.Results: Application of the Reina framework demonstrates how trust can be maintained through collaborative renegotiation of job expectations, confidential and respectful communication practices, and strategies that preserve professional identity during treatment and reintegration. The model further positions return to use as an opportunity for structured trust repair rather than moral failure, enabling organizations to address safety or performance concerns while maintaining dignity and continuity of employment.Conclusion: Aligning recovery-ready workplace practices with Reina trust behaviors offers a pragmatic, behaviorally grounded approach to responding to substance use disorders. A trust-based strategy may reduce stigma, improve retention, support workforce stability, and mitigate the financial and operational consequences of employee turnover while promoting humane and accountable responses to recovery.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-informed approaches to medication management for opioid use disorder in special populations: a narrative review. 特殊人群阿片类药物使用障碍的循证用药管理方法：叙述性回顾。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-07 DOI: 10.1080/10550887.2026.2695127

Zahraa Atoui, Adam Fakhri, Aniket Malhotra, Yi-Lang Tang

{"title":"Evidence-informed approaches to medication management for opioid use disorder in special populations: a narrative review.","authors":"Zahraa Atoui, Adam Fakhri, Aniket Malhotra, Yi-Lang Tang","doi":"10.1080/10550887.2026.2695127","DOIUrl":"https://doi.org/10.1080/10550887.2026.2695127","url":null,"abstract":"Opioid use disorder remains a critical public health challenge, marked by high prevalence, overdose deaths, and substantial societal burden. Despite the availability of effective medications for OUD (MOUD), treatment utilization remains suboptimal, particularly among special populations. Contributing factors include altered pharmacokinetics, complex comorbidities, heightened safety concerns, stigma, and limited clinician expertise. This review comprehensively summarizes the latest evidence and guidelines to inform approaches to medications for opioid use disorder in special populations, including individuals with hepatic, renal, or cardiovascular disease; HIV/AIDS; peripartum or breastfeeding status; concurrent alcohol or benzodiazepine use; perioperative care needs; and adolescence. Across these populations, MOUD are associated with reduced morbidity and mortality and should not be withheld solely due to medical comorbidity, pregnancy, concurrent substance use, or perioperative care needs. Methadone is consistently associated with the highest treatment retention but requires careful dosing and monitoring in patients with hepatic, renal, and cardiovascular disease and in those receiving interacting medications, including antiretroviral therapy. Buprenorphine demonstrates a favorable safety profile across medically complex populations and fewer clinically significant drug-drug interactions. Extended-release naltrexone may be appropriate for select patients who can maintain opioid abstinence prior to induction, though its use is constrained by initiation barriers and limited population-specific data. Persistent access gaps, particularly among adolescents, highlight the need for tailored implementation strategies and further research. Consequently, recognizing the distinct needs and barriers of special populations with OUD is essential, and tailoring care to these considerations can enhance treatment outcomes.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148399561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic overlapping pain conditions in individuals with active opioid use disorder: a descriptive study of syringe program participants. 活动性阿片类药物使用障碍个体的慢性重叠疼痛状况：注射器计划参与者的描述性研究。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-09-02 DOI: 10.1080/10550887.2025.2541133

Johnathan Rausch, Steven E Harte, David A Williams, Daniel J Clauw, Megan Deaner, Leon Brodsky, Jace Floyd, Orman Trent Hall

{"title":"Chronic overlapping pain conditions in individuals with active opioid use disorder: a descriptive study of syringe program participants.","authors":"Johnathan Rausch, Steven E Harte, David A Williams, Daniel J Clauw, Megan Deaner, Leon Brodsky, Jace Floyd, Orman Trent Hall","doi":"10.1080/10550887.2025.2541133","DOIUrl":"10.1080/10550887.2025.2541133","url":null,"abstract":"Background: Comorbidity between opioid use disorder (OUD) and chronic pain is substantial. Pain has been shown to be a motivator for OUD onset, maintenance, relapse, and treatment delay. A cluster of pain conditions known as chronic overlapping pain conditions (COPCs), also now referred to in contemporary ICD classification as primary pain conditions, are particularly refractory to traditional forms of pain treatment, and likely adversely impact comorbid OUD.Objective: This cross-sectional descriptive study sought to obtain a better understanding of the prevalence of COPCs among individuals with OUD.Methods: The COPCs screener was originally developed to address the challenges of readily assessing for multiple of these conditions; which is important given that the number of said conditions acts as a marker for the likely presence of nociplastic pain. This screener was used alongside supplementary survey items to describe COPCs and pain distribution in a sample of individuals with active OUD recruited from a syringe exchange program.Results: Comparisons of COPC prevalence between the study sample and global prevalence estimates found that among those with OUD, there is a significantly higher-than-expected prevalence of chronic low back pain, myalgic encephalomyelitis/chronic fatigue syndrome, chronic migraine headache, and fibromyalgia.Conclusions: Results support further investigations into COPCs in the context of OUD. Further research may reveal methods of enhancing OUD treatment and identifying additional targets for intervention and prevention.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"294-303"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thyroid function in alcohol use disorder: a case-control and longitudinal study of gender, Alcohol-Induced Psychotic Disorders, and detoxification effects. 酒精使用障碍中的甲状腺功能：性别、酒精诱发的精神障碍和解毒效果的病例对照和纵向研究

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-11-11 DOI: 10.1080/10550887.2025.2581471

Qing Yu, Caihong Ye, Sili Wang, Zhenzhou Zheng, Quansheng Sun, Yuanbin Wang

{"title":"Thyroid function in alcohol use disorder: a case-control and longitudinal study of gender, Alcohol-Induced Psychotic Disorders, and detoxification effects.","authors":"Qing Yu, Caihong Ye, Sili Wang, Zhenzhou Zheng, Quansheng Sun, Yuanbin Wang","doi":"10.1080/10550887.2025.2581471","DOIUrl":"10.1080/10550887.2025.2581471","url":null,"abstract":"Methods: In this retrospective case-control study we enrolled 283 patients with AUD (261 men, 22 women) admitted between 2021 and 2024, of whom 80 had AIPD. Baseline levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroxine (T4) and triiodothyronine (T3) were measured at the time of admission. A second measurement was performed three to four weeks after detoxification. Baseline values were compared with those of 300 age- and sex-matched healthy controls. Longitudinal changes within the AUD cohort and differences between AIPD and non-AIPD subgroups were analyzed by paired t-tests and chi-square tests as appropriate.Results: Mean serum levels of FT4, FT3, T4 and T3 were significantly lower in AUD patients than in healthy controls, while TSH had no significant change. In the same comparison, the proportion of individuals with abnormal thyroid parameters was higher in the AUD group than in controls. Among AUD patients, women, showed a higher proportion of elevated TSH, and reduced FT4, FT3 and T3 than men with AUD. The level of thyroid hormone in patients with AIPD was higher than that in patients with Non-AIPD, and after detoxification treatment, thyroid function may not necessarily return to normal, but showed a trend of thyroid hormone decreased and TSH increased, which was more pronounced in AIPD patients.Conclusion: AUD can lead to thyroid dysfunction. Patients with AUD should closely monitor their thyroid hormone levels to prevent the worsening of psychiatric and neurological symptoms.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"318-326"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intersectional disparities in illicit drug use by race/ethnicity and sexual orientation among U.S. adults: Results from a large secondary sample. 在美国成年人中，种族/民族和性取向在非法药物使用方面的交叉差异：来自大型二次样本的结果。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-06-19 DOI: 10.1080/10550887.2025.2514322

Jung-Chi Chew, Yen-Chang Chang, Yen-Han Lee

{"title":"Intersectional disparities in illicit drug use by race/ethnicity and sexual orientation among U.S. adults: Results from a large secondary sample.","authors":"Jung-Chi Chew, Yen-Chang Chang, Yen-Han Lee","doi":"10.1080/10550887.2025.2514322","DOIUrl":"10.1080/10550887.2025.2514322","url":null,"abstract":"Background: Illicit drug use disparities persist across racial and ethnic and sexual identity groups. This study examined associations between sexual identity, race/ethnicity, and drug use patterns, focusing on types and usage within the past year.Methods: Using data from the 2021-2023 National Survey on Drug Use and Health (n = 129,823), multinomial logistic regression was used to assess drug use patterns. Key predictors included sexual identity (heterosexual, lesbian/gay, and bisexual) and race/ethnicity (White, Black, Asian, Hispanic, and Others), controlling for socioeconomic factors.Results: Bisexual individuals had the highest drug use rates among sexual minority groups, particularly for polysubstance use (14.29%). White individuals reported the highest overall prevalence (72.55%), while Black and Asian individuals had lower rates. Drug use was highest among young adults (32.01%) and declined with age. Among racial groups, Black individuals exhibited the highest drug misuse risk (interaction model: single-drug use RRR = 2.70, 95% CI = [2.38, 3.05]; polysubstance use RRR = 1.70, 95% CI = [1.48, 1.95]), followed by Asian individuals (single-drug use RRR = 2.21, 95% CI = [1.72, 2.85]; polysubstance use RRR = 1.78, 95% CI = [1.38, 2.30]). Among sexual identity groups, Black bisexual individuals were the most vulnerable (RRR = 1.50, 95% CI = [1.03, 2.19]), highlighting the compounded risks faced by individuals at the intersection of racial and sexual minority identities.Conclusions: Findings emphasize the need for culturally responsive interventions targeting bisexual individuals and racial/ethnic minorities to reduce disparities and improve public health outcomes.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"257-266"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serotonin Syndrome Masquerading as Alcohol Withdrawal: A Case Report. 5 -羟色胺综合征伪装成酒精戒断：一例报告。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-08-31 DOI: 10.1080/10550887.2025.2545649

Mirsol Choi, Xena Wang, Mohit Singh, Jeremy Weleff

{"title":"Serotonin Syndrome Masquerading as Alcohol Withdrawal: A Case Report.","authors":"Mirsol Choi, Xena Wang, Mohit Singh, Jeremy Weleff","doi":"10.1080/10550887.2025.2545649","DOIUrl":"10.1080/10550887.2025.2545649","url":null,"abstract":"Introduction: Alcohol withdrawal syndrome (AWS) and serotonin syndrome (SS) share several overlapping symptoms, complicating diagnosis in patients with alcohol use disorder (AUD) on serotonergic treatment.Case presentation: We describe a 54-year-old male with a history of AUD and anxiety disorder who presented to a residential treatment center after patient report about 11 days of alcohol abstinence. Despite an initially mild withdrawal course, he developed worsening tremors, nausea, diarrhea, diaphoresis, muscle twitching, rigidity, and restlessness beyond the typical AWS timeframe. His medication regimen included multiple serotonergic agents. Neurological examination revealed hyperreflexia, clonus, and persistent hypertension, fulfilling the Hunter Serotonin Toxicity Criteria for SS. All serotonergic medications were discontinued and supportive care was initiated, leading to rapid symptom improvement and resolution.Conclusions: Thorough evaluation of medication history and symptom timeline during clinical assessment is critical for differentiating AWS and SS. Clinicians are encouraged to remain vigilant for SS in patients with AUD on serotonergic agents to prevent adverse outcomes and potential mortality.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"364-371"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of treatment-refractory opioid use disorder: a case-series of a modified maintenance protocol. 难治性阿片类药物使用障碍的管理：修改后的维持方案的病例系列。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-11-20 DOI: 10.1080/10550887.2025.2581489

William Rioux, Jeremy Weleff, Cristina Zaganelli, Lovneet Hayer, Sumantra Monty Ghosh

{"title":"Management of treatment-refractory opioid use disorder: a case-series of a modified maintenance protocol.","authors":"William Rioux, Jeremy Weleff, Cristina Zaganelli, Lovneet Hayer, Sumantra Monty Ghosh","doi":"10.1080/10550887.2025.2581489","DOIUrl":"10.1080/10550887.2025.2581489","url":null,"abstract":"Background and objectives: Reaching the maintenance phase and reducing illicit substance use in those with severe opioid use disorder (OUD) remains a large clinical challenge. The use of intravenous opioid agonist treatment has become a last-line treatment for severe OUD. In this case series, we describe a novel form of this treatment using both long-acting buprenorphine and injectable hydromorphone.Methods: Retrospective chart review of cases in specialized enhanced addiction treatment centers in Alberta, Canada of patients prescribed long-acting injectable buprenorphine and intravenous hydromorphone.Results: We describe four cases of males ranging from 39 to 64 years of age with treatment-refractory opioid use disorder and multiple concurrent mental health and social issues who have experienced various periods of stability on long-acting injectable buprenorphine and along with intravenous hydromorphone or slow release oral morphine).Discussion and conclusions: This case series presents a novel treatment combining buprenorphine extended-release injection with hydromorphone or slow release oral morphine for individuals with OUD who have not responded to standard opioid agonist treatment. The approach showed promise in managing withdrawal and cravings, potentially improving treatment retention. Further research is needed to evaluate long-term outcomes and optimize retention strategies to reduce opioid-related mortality.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"351-357"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mephentermine misuse: an emerging challenge and the potential role of mirtazapine-a case report. 甲非明误用：新出现的挑战和米氮平的潜在作用——一个病例报告。

IF 1.7 4区医学

Journal of Addictive Diseases Pub Date : 2026-07-01 Epub Date: 2025-06-21 DOI: 10.1080/10550887.2025.2514287

Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas

{"title":"Mephentermine misuse: an emerging challenge and the potential role of mirtazapine-a case report.","authors":"Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas","doi":"10.1080/10550887.2025.2514287","DOIUrl":"10.1080/10550887.2025.2514287","url":null,"abstract":"Mephentermine is a sympathomimetic amine with structural and pharmacological similarities to amphetamines. Despite its increasing misuse, particularly among athletes and bodybuilders, there is limited literature on its management. No pharmacological treatments have been approved for mephentermine misuse. We describe two cases of young adult males presenting with symptoms of mephentermine withdrawal, including insomnia, anxiety, and craving. Both had histories of prolonged intravenous mephentermine use, with one managed on an outpatient basis and the other as an inpatient. Mirtazapine was initiated in both cases and was associated with improvements in sleep, anxiety, craving and hyperarousal. Psychotic symptoms in one patient resolved with short-term risperidone. Both patients received brief motivational enhancement therapy and remained abstinent from all substances except tobacco during two months of follow-up. These cases highlight the potential utility of mirtazapine in managing mephentermine misuse, particularly for addressing withdrawal symptoms and craving. Given its noradrenergic and serotonergic profile and its demonstrated efficacy in methamphetamine use, mirtazapine may be a promising candidate for treatment. However, the findings are limited by the case series design and larger, controlled studies are needed to confirm its role in clinical management.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"358-363"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0